Medicine

Lessons coming from a bad genetics treatment trial for Duchenne muscular dystrophy

.Attribute Medicine, Published online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec received FDA confirmation after an adverse test, which highlights the many complications and also challenges of medicine development in this setting.